Clearstead Advisors’s Recursion Pharmaceuticals RXRX Stock Holding History
Bought
Maintained
Sold
Other funds holding RXRX
MCMU
Clearstead Advisors's RXRX Position: Q2 2026 in Review
Clearstead Advisors opened a new position in Recursion Pharmaceuticals (RXRX) in Q2 2026: 30,062 shares worth $110K. The stake represents ﹤0.01% of the portfolio and ranks #1264 among its holdings. This is a return to the name: Clearstead Advisors previously reported a position in RXRX as recently as Q4 2025.
Clearstead Advisors first reported a position in RXRX in Q3 2023 and has held it in 6 quarters since. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.
- Clearstead Advisors held 30,062 shares of Recursion Pharmaceuticals worth $110K as of Q2 2026.
- Recursion Pharmaceuticals was a new Clearstead Advisors position in Q2 2026.
- Recursion Pharmaceuticals made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #1264 holding.
- Clearstead Advisors first reported a position in Recursion Pharmaceuticals in Q3 2023 and has held it in 6 quarters since.
- 343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.
Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.